Crisis brings danger and opportunity. The COVID-19 pandemic will go down in history as an unprecedented crisis in the modern world, causing disruption and high death rates in nearly every country. The long-term impact of the pandemic is yet to be assessed. There are fears of a second wave and of deepening economic recession. Social inequality has increased, but there are also local and national initiatives providing help to those most in need. Scientists are responding to the desperate calls for effective vaccines and medications. Many research studies are underway and the knowledge that is gathered is shared and expanded internationally. As the lockdown is lifted and restrictions eased, we face the challenge of deciding whether to build on what we have learnt, or revert to our old ways.

The journal offers author benefits which include:

• The copyright of their own research outcomes, concepts and expert opinions
• Post-publication promotion of the published articles for enhanced visibility and citation probability
• Special discounts on processing charges based on the number, relevance and impact of the submissions
• Publication of the article within one week after the acceptance by the peer-reviewers (fast track review)

Journal accepts original manuscripts in the form of Research Articles, Review Articles, Clinical Reviews, Commentaries, Case Reports, Perspectives and Short Communications .

You can Submit manuscript directly online https://www.imedpub.com/submissions/dual-diagnosis-open-access.html or as an attachment to this E-mail: dualdiagnosis@emedsci.com

Articles will be paid high attention during the Publication any immediate submission is highly appreciable.

Regards,
Nancy Ella
Journal Editor
Dual Diagnosis: Open Access
WhatsApp: +1-947-333-4405